Clinical trials: Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

• Completed
• Age: 18 to 65 years
• Phase 2

This is a Phase IIa, open-label, randomized study in treatment-naïve, sputum smear-positive patients with drug-sensitive pulmonary TB to assess the early bactericidal activity of telacebec (Q203).

Trial name

NCT03563599

Testing

Telacebec (Q203), Rifafour e-275

Where

2 sites in South Africa

Volunteers

60 people

Sponsor

Qurient Co., Ltd.